baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

BNP Paribas Discount Zert REGN 29.../ DE000PC1SUU4 /

24/05/2024 10:20:21	Chg.-0.930	Bid10:21:25	Ask10:21:25	Underlying	Strike price	Expiration date	Option type
777.330EUR	-0.12%	777.480 Bid Size: 24	802.160 Ask Size: 24	Regeneron Pharmaceut...	- USD	29/12/2025	Call

GlobeNewswire 23/05 Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Com...

GlobeNewswire 22/05 Invivyd Elects Two New Independent Members to its Board of Directors

GlobeNewswire 21/05 Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update

GlobeNewswire 20/05 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharma...

GlobeNewswire 20/05 Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS...

GlobeNewswire 20/05 Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ...

GlobeNewswire 20/05 Bragar Eagel & Squire, P.C. Is Investigating Zymeworks, Regeneron, Jabil, and DoubleVerify and Encou...

GlobeNewswire 17/05 More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International ...

GlobeNewswire 14/05 Veru Announces Mitchell Steiner as Keynote Speaker at Biomed Israel 2024: The 22nd National Life Sci...

GlobeNewswire 14/05 Viracta Therapeutics Appoints Michael Faerm as Chief Financial Officer

GlobeNewswire 13/05 Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chroni...

GlobeNewswire 10/05 Prime Medicine Reports First Quarter 2024 Financial Results and Provides Business Updates

GlobeNewswire 09/05 Intellia Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Company P...

GlobeNewswire 08/05 Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound G...

GlobeNewswire 07/05 Kiniksa Pharmaceuticals to Present at Bank of America Securities 2024 Health Care Conference

GlobeNewswire 06/05 Regeneron Announces Investor Conference Presentations

GlobeNewswire 02/05 Regeneron Reports First Quarter 2024 Financial and Operating Results

GlobeNewswire 29/04 EYLEA® HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Sustained and Clinically Mean...

GlobeNewswire 26/04 Medigene AG reports Financial Results and Business Update for Q1 2024

GlobeNewswire 25/04 Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing fo...

GlobeNewswire 24/04 Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad R...

GlobeNewswire 23/04 Kiniksa Pharmaceuticals Reports First Quarter 2024 Financial Results and Recent Portfolio Execution

GlobeNewswire 22/04 Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Th...

GlobeNewswire 18/04 Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Regeneron Pharmaceuticals,...

GlobeNewswire 18/04 REGENERON ALERT: Bragar Eagel & Squire, P.C. is Investigating Regeneron Pharmaceuticals, Inc. on Beh...

BNP Paribas Discount Zert REGN 29.../ DE000PC1SUU4 /

If you wish to receive reply to your feedback, please provide your email address.